Staurosporine derivatives for use in alveolar rhabdomyosarcoma

Details Staurosporine derivatives for use in alveolar rhabdomyosarcoma Staurosporine derivatives for use in alveolar rhabdomyosarcoma

2011-07-05

2011-07-05

Hui, Sam-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S211090

Reexamination Certificate

active

07973032

ABSTRACT:
This invention relates to staurosporine derivatives are effective when used in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a disease associated with a PAX/FKHR translocation including a PAX3/FKHR translocation and a PAX7/FKHR translocation, more especially a solid tumor disease such as a Sarcoma, most especially an Alveolar Rhabdomyosarcoma.

REFERENCES:
patent: 5093330 (1992-03-01), Caravatti et al.
patent: 6284751 (2001-09-01), Aiello et al.
patent: 2003/0096875 (2003-05-01), Burton et al.
patent: WO97/04761 (1997-02-01), None
patent: WO 97/04761 (1997-02-01), None
patent: WO03/037347 (2003-05-01), None
patent: WO 03/037347 (2003-05-01), None
patent: WO2004/112794 (2004-12-01), None
patent: WO 2004/112794 (2004-12-01), None
patent: WO 2005/027971 (2005-03-01), None
patent: WO2005/027971 (2005-03-01), None
Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, and Schäfer BW, “Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins,” Proceedings of the National Academy of Sciences, Nov. 1996, 93(23), 13164-13169.
Bouché M, Zappelli F, Polimeni M, Adamo S, Wetsel WC, Senni MI, and Molinaro M, “Rapid activation and down-regulation of protein kinase C alpha in 12-O-Tetradecanoylphorbol-13-acetate-induced differentiation of human rhabdomyosarcoma cells,” Cell Growth and Differentiation, Jul. 1995, 6(7), 845-852.
Way D, Smith S, Sivendran S, Chie L, Kanovsky M, Brandt-Rauf PW, Chung DL, Michl J, and Pincus MR, “A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide,” Cancer Chemotherapy and Pharmacology, Jun. 2002, 49(6), 429-437.
Bernasconi et al., Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins, Proc. Nat. Acad. Sci., USA, vol. 93, pp. 13164-13169 (1996).

Affiliated with

Also associated with

Rating

Staurosporine derivatives for use in alveolar rhabdomyosarcoma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Staurosporine derivatives for use in alveolar rhabdomyosarcoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staurosporine derivatives for use in alveolar rhabdomyosarcoma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2658815